Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 24, 2009

Tamoxifen Resistance Linked to Heightened Growth Factor Signaling

  • Some estrogen receptor-positive (ER+) breast cancers respond poorly to tamoxifen because of increased growth factor (GF) signaling, according to a team of scientists. The study is published in BMC Medical Genomics in a paper titled “Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer.”

    To investigate the differences between those ER+ cancers that respond well to Tamoxifen (luminal-A) and those that do not (luminal-B), the researchers used a computational method of gene-expression analysis called gene set enrichment analysis (GSEA).

    They found increased growth factor activation in the gene-expression profiles of nearly 100 luminal-B breast cancer samples. They also showed that treatment with the growth factor heregulin, which induced growth factor signaling in an in vitro model, could overcome tamoxifen-induced cell cycle arrest.

    “We propose that activation of GF signaling contributes to this highly proliferative, relatively tamoxifen-insensitive phenotype and that this exists independently of HER2 overexpression,” explains Sherene Loi, from the Peter MacCallum Cancer Centre, Melbourne.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »